Posts by Satoshi Yoda, MD, PhD
-
MET Alterations Are a Recurring Resistance Mechanism in ALK-Positive Lung Cancer
Massachusetts General Hospital Cancer Center researchers find that ALK/MET combination therapy is a rational approach to treatment of ALK-positive non-small-cell lung cancer.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
